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ABSTRACT 
 
Brian H. Constance:  The role of tau in Alzheimer’s Disease:  Effects of Lys-280 and Lys-281 
acetylation on tau function and structure 
(Under the direction of Todd J. Cohen) 
 
 The tau protein is implicated in Alzheimer’s disease (AD), and it is a prominent feature 
of AD pathology.  In AD, tau's normal ability to stabilize microtubules (MTs) is impaired, and 
tau becomes aggregated.  Aberrant post-translational modifications (PTMs) of tau may provide 
an explanation for why this occurs.  There are mounting indications that tau acetylation plays a 
role in AD, with acetylated K280 being discovered as a marker of tau aggregation in AD brain. 
We hypothesize that acetylation of lysines in tau’s microtubule binding region (MTBR) causes a 
loss of tau stabilizing function and a gain of propensity to form aggregates.  Using lysine to 
glutamine (KQ) mutations to model acetylation, we provide evidence suggesting that single 
(K280) or double (K280/K281) acetylation inhibits MT assembly.  Furthermore, we implicate 
the K280 acetylation in accelerating tau aggregation, and in the seeding of aberrantly 
phosphorylated, tau aggregation. 
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CHAPTER ONE:  THE ROLE OF TAU IN ALZHEIMER’S DISEASE:  EFFECTS OF 
LYS-280 AND LYS-281 ACETYLATION ON TAU FUNCTION AND STRUCTURE 
 
Introduction 
Over the next few decades, the number of Alzheimer’s disease (AD) patients in the US is 
estimated to triple, placing a heavy burden on patients, their families, and our country. Great 
strides have been made in understanding some of the characteristic features of AD, but we have 
yet to uncover the causes and key mechanisms.  Protein aggregation in the central nervous 
system (CNS) is one of the features of AD, and the severity of aggregation correlates with 
severity of disease.  The propensity of two particular proteins, amyloid-β (Aβ) and tau, to form 
aggregates in AD brain has been the focus of intense research to determine what initiates and 
sustains aggregation, and whether the aggregates themselves or a secondary consequence of the 
aggregation cause neurodegeneration.  The Aβ protein accumulates in the extracellular space 
while the tau protein accumulates predominantly inside cells in the CNS.  During AD 
progression, the appearance of tau aggregates happens prior to the appearance of Aβ aggregates 
(Braak and Del Tredici, 2015; Braak and Braak, 1997; Braak et al., 2013).  Studies using mouse 
models of dementia have suggested a pathological relationship between Aβ and tau.  A recent 
review ascribed the role of Aβ to a “trigger” and the role of tau to a “bullet” (Bloom, 2014).  In 
mouse models in which a mutant human tau was over-expressed, the presence of Aβ intensified 
tau pathology (Götz J et al., 2001; Lewis et al., 2001; Hurtado et al., 2010).  When tau is knocked 
out of a mouse model over-expressing the gene that produces the precursor protein of Aβ, the 
mice exhibited reduced neuron loss and improved memory retention and survival (Roberson et 
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al., 2007).  One extension of the mouse model data to AD is that neurodegeneration and 
accompanying memory loss is dependent on the actions of the tau protein and that tau’s effects 
can be worsened in the presence of Aβ.  Support for the idea that neurodegeneration is dependent 
on the actions of tau comes from other neurodegenerative diseases where the predominant 
observed pathology is tau aggregation (Williams, 2006).  Some of the normal properties of tau 
are to bind, assemble, and stabilize microtubules (MTs) (Cleveland et al., 1977; Drubin et al., 
1986).  In AD, the tau is less able to bind to MTs and draws other normal, soluble tau and other 
microtubule associated proteins (MAPs) into aggregates inside neurons.  One byproduct of this 
intra-neuronal protein aggregation is a less stable and functional transport cytoskeletal network 
(e.g. MTs).  These data encouraged us to continue to elucidate the role tau plays in AD, 
specifically looking at the effects of tau K280 or K280/K281 acetylation on tau’s function and 
structure. 
 
What is tau’s normal structure and physiological function? 
There are six predominant isoforms of the tau protein known to be expressed in humans.  
These six isoforms are created by alternative splicing with the resultant proteins including or 
excluding two regions near the N-terminus (0N, 1N, or 2N) and containing either three or four 
repeat sequences towards the C-terminus (3R or 4R) (Goedert et al., 1988, Goedert et al., 1989a, 
Goedert et al., 1989b).  It is important to note that in the case of 3R, the splicing removes an 
interior, 2nd repeat, which includes the K280 and K281 residues.  Tau is plentiful in neurons of 
brain tissue (Lee et al. 2001; Trojanowski et al, 1989) and is thought to predominantly retain a 
disordered structure.  As mentioned above, tau acts to bind, assemble and stabilize MTs.  This 
increased MT stability is a result of direct interactions between tau and MTs, such as bonds 
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between tau and MTs.  Previous work has identified that the 3-4 tandem repeats are the main 
region of tau-MT interaction, and that these interactions are strengthened by the proline-rich 
region of tau toward the N-terminus (Lee et al., 1989; Goode et al., 1997; Gustke et al., 1994).  
Other MAPs are also located in neurons such as MAP1B and MAP2 (Morris et al., 2011), but to 
date, tau is the MAP predominantly linked to AD pathology.  Largely due to tau’s ability to bind 
to other proteins besides MTs, more recent studies have investigated additional physiological 
roles for tau.  Data suggests that tau acts as a protein scaffold (Ittner et al., 2010; Klein et al., 
2002), and there are hints that tau might also have a role in signaling that affects neurite 
outgrowth (Dawson et al., 2001).  Tau is also known to be post-translationally modified in 
control brain; it is phosphorylated with a stoichiometry of 2-3 moles of phosphate for every 1 
mole of tau protein (Köpke E et al., 1993). 
 
Are there pathogenic tau mutations in Alzheimer’s disease? 
We know that gene mutations have causal association to forms of cancer and other types 
of neurodegenerative disease besides AD (Bos et al., 1987; Forrester et al., 1987; Rodenhuis et 
al., 1987; Smit et al., 1988; Taddei et al., 2002; Singleton, 2005; Ghetti et al., 2015).  
Interestingly, approximately 50 mutations of tau have been causally linked to frontotemporal 
dementia with parkinsonism linked to chromosome-17 (FTDP-17) (Ghetti et al., 2015).  About 
half of these tau mutations are known to promote tau pathology (e.g. tau aggregates) (Ghetti et 
al., 2015); two of these aggregate-prone mutations occur at Pro-301, P301S and P301L.  
Inherited in an autosomal dominant fashion, FTDP-17 makes up only a small fraction of all cases 
of dementia.  In contrast, Alzheimer’s disease, is the most common form of dementia.  While tau 
mutations have recently been identified in single cases or small cohorts of AD patients (Jin et al., 
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2012; Momeni et al., 2009), these mutations are not the norm when we take all other AD cases 
into account, and more importantly their pathogenicity is not validated.  With no clear driver 
mutations of tau in AD, some of our understanding of tau in the context of neurodegenerative 
disease has been born out of research using the P301S and P301L aggregate-prone tau mutations 
found in FTDP-17.  Indeed, labs have leveraged in vitro studies with these mutations as well as 
used mouse models expressing human tau with these two point mutations of proline (von Bergen 
et al., 2001; Iba et al., 2013; Song et al., 2015). 
 
Do tau PTMs play a role in AD progression? 
With tau mutations being an unlikely source of its role in AD, we and others have 
focused on whether aberrant PTMs drive the disease process.  Early research on the paired 
helical filament (PHFs) portion of AD neurofibrillary tangle (NFT) pathology identified (1) that 
tau was a core component of the PHF aggregates and that (2) tau was post-translationally 
modified in these PHFs (Iqbal et al., 1991; Gong et al., 2005).  In the previous ~30 years of tau 
research, the tau in PHFs have been noted to be modified by truncation, glycation, glycosylation, 
nitration, polyamination, ubiquitination and abnormal phosphorylation (Grundke-Iqbal et al., 
1988; Grundke-Iqbal et al., 1986; Iqbal et al., 1989, Flament et al., 1989; Gong et al., 2005).  
Aberrant tau phosphorylation has been the main focus of attention for the previous 30 years.  
There are reportedly 75 sites of phosphorylation on the tau protein, of which at least 23 also have 
been reported as being observed in AD brain (Luna-Muñoz et al., 2013; Cook et al., 2014a).  In 
AD, tau can be phosphorylated at a stoichiometry at least 3 times greater than that in a control 
brain, as compared to the 2-3 moles of phosphorylated tau to every 1 mole of tau (Köpke et al., 
1993).  The kinases implicated in driving aberrant tau phosphorylation in AD include Fyn 
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(Shirazi & Wood, 1993), glycogen synthase kinase 3β (Flaherty et al., 2000; Jin et al., 2015), and 
isoforms in the microtubule affinity-regulating kinase (MARK) family (Chin et al., 2000; Gu et 
al., 2013).  The protein phosphatase 2A (PP2A) is also known to be dysregulated in brains of 
those afflicted with AD (Wang et al., 2015; Liu et al., 2005; Tanimukai et al., 2005).  With the 
prevailing thought being that tau must be off microtubules to cause the loss of MT stability as 
well as form aggregates, it is puzzling that many of tau’s phosphorylation sites are outside of the 
region of tau that confers MT binding.  When specific sites of tau are phosphorylated, tau is 
unable to bind to MTs, which can lead to MT instability (Biernat et al., 1993).  Studies have not 
always been decisive on whether identified sites of aberrant tau phosphorylation in AD serve to 
both impair tau-MT binding and promote the formation of NFTs (Rankin et al., 2005; Schneider 
et al., 1999).  For example, aberrant phosphorylation within the microtubule-binding region 
(MTBR) at S262 induces a loss of binding to MT, but does not induce an aggregate-prone 
phenotype (Schneider et al., 1999).  One possible explanation for the loss of MT binding and 
aggregation is that that each site of post-translational modification relays a slightly different 
message in the cell, and that these modifications work in concert with the other known PTMs to 
lead the tau to become unbound from MTs and aggregated.  Another proposal is that there are 
certain sites that, when modified, both impair tau’s binding to MTs and also promote tau’s 
aggregation. 
In 2010-13, it was reported that tau could also be acetylated, and that this modification 
was linked to AD and other tauopathies (Min et al., 2010; Cohen et al., 2011; Irwin et al., 2012; 
Irwin et al., 2013).  The mechanism by which tau is acetylated in vivo remains somewhat cloudy, 
but in vitro data demonstrated that (1) Creb-binding protein (CBP) is capable of acetylating tau’s 
MTBR (Min et al., 2010; Cohen et al., 2011) and that (2) tau can self-acetylate without presence 
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of another acetyltransferase (Cohen et al., 2013).  The deacetylases, sirtuin 1 (SIRT1) and 
histone deacetylase 6 (HDAC6), have both been implicated in deacetylating tau (Ding et al., 
2008; Min et al., 2010; Cohen et al., 2011).  Tau acetylation research was also instrumental in 
identifying K280 and K281 as human disease relevant sites of tau acetylation.  Importantly, 
aggregates of tau in AD mouse models and AD brain were discovered to be positive for 
acetylated K280 through the use of an anti-acetylated K280 tau antibody (Cohen et al., 2011).  
The first clues as to whether acetylation of tau promotes aggregation and impairs normal tau 
function were also presented.  Artificial acetylation of tau with CBP in vitro promoted tau 
fibrillization relative to WT tau and also impaired tubulin polymerization (Cohen et al., 2011). 
These findings hinted at a pathogenic role for acetylated tau in AD.  However, an exact 
role of tau acetylation in AD remained elusive.  For example, certain sites of tau acetylation may 
be more important than others in regulating tau’s function and propensity to aggregate.  Recent 
studies within the last year have reported that single or combination lysine acetylation mimics of 
tau (e.g. K174Q, K274Q, K280Q, or K281Q) can produce neurodegenerative and behavioral 
phenotypes in vivo (Min et al., 2015; Sohn et al., 2016; Gorsky et al., 2016; Tracy et al., 2016).  
Additionally, older data was also suggestive that K274, K280, and K281 have direct contact with 
MTs (Goode and Feinstein, 1994). 
Another developing area of AD research have been studies targeted at explaining how 
hallmark AD pathology (e.g. tau aggregation) spreads as the disease worsens.  We think that tau 
PTMs will help advance knowledge in this area, and we hypothesize that tau acetylation plays a 
role in the spread of tau pathology.  Over the course of AD, the severity of the disease tracks 
well with the prevalence of tau pathology (Braak and Tredici, 2015).  A recent study also 
provides evidence that tau pathology has a characteristic anatomical spread as the disease 
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worsens (Brettschneider et al., 2015).  The tau aggregates are found early on in the locus 
coeruleus, then over time can be found in the transentorhinal cortex, and eventually the 
hippocampus and neocortex (Brettschneider et al., 2015).  The same article also diagrammed the 
anatomical spread of the other hallmark pathology in AD, Aβ.  Intriguingly, the spreading of Aβ 
appears to be in the opposite direction of spreading of tau pathology; in the case of Aβ it is 
observed from the neocortex inward as AD progresses. 
One molecular explanation for the spread of tau pathology is that mis-folded, aberrantly 
modified tau from a donor cell gets out of the cell and acts as a seed for tau pathology in 
neighboring cells.  The seeding would cause the neighboring cell’s tau to become mis-folded, 
aberrantly modified, and eventually pathological NFTs would form.  In the body of literature, 
this process has been termed seeding as well as template-directed mis-folding.  Tau, as well as 
Aβ, have also been considered prion-like, due to the cell to cell spreading that may occur in AD. 
While there have been no reported models to test directly if tau acetylation promotes cell 
to cell spreading, there have been some studies that allow for inferences that tau acetylation is 
involved.  Models where Aβ levels are increased led to increase in tau acetylation; this could 
place tau acetylation downstream of Aβ action in AD, and could mean that tau becomes 
acetylated when it and Aβ have both spread to the same regions of the brain from different 
starting points (Cohen et al., 2011; Min et al., 2010; Brettschneider et al., 2015).  Additionally, 
when tau fibrils are injected into the hippocampus of mice expressing P301S mutant human tau 
(PS19 line) predisposed to generating tau aggregates, there was an increase in tau acetylation two 
weeks after injection (Iba et al., 2013).  This could also foreshadow a role for acetylated tau in 
the initiation and propagation of tau pathology. 
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Here, we have focused on three outcomes of aberrant acetylation of tau: (1) whether it 
induces a loss of physiological MT assembly function, (2) whether it can accelerate tau 
aggregation, and (3) whether it worsens tau’s propensity for template-directed mis-folding (ie. 
seeding).  Importantly, our data indicates that acetylation of K280 is sufficient to both drive loss 
of tau’s MT assembly function and promote the generation of insoluble tau, and that additional 
acetylation of K281 worsens the loss of tau’s MT assembly function.  We also provide 
preliminary data that the K280 acetylation interacts with phosphorylation mechanisms, with 
increases in phosphorylation at sites associated with AD tau pathology when we tested K280 site 
acetylation in our seeding cell-based assays.  Taken together, this work is supportive of the 
hypothesis that acetylation of K280 or double acetylation of K280/K281 are pathogenic PTMs in 
AD. 
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Methods and Materials 
 
Plasmids and Cell Culture. For QBI-293 cell seeding experiments, the full-length tau isoform 
containing both N-terminal inserts and all four repeat domains (designated tau-T40).  Tau-T40 
plasmids were cloned into the pcDNA5/TO vector (Life Technologies).  The K→Q, K→R, and 
P→L tau mutations were created using site-directed mutagenesis (NEB).  QBI-293 cells were 
grown in full Dulbecco's Modified Eagle's Medium (DMEM) media (supplemented with 10% 
fetal bovine serum (FBS), 1X L-glutamine, and 1X penicillin/streptomycin), and FuGENE® 6 
transfection reagent (Promega) was used to perform the QBI-293 cell transfections. 
 
Protein Expression and Purification. Protein expression, extraction, and purification was 
performed using chromatography methodology to purify heat stable tau proteins.  Tau-K18 and 
tau-T40 plasmids were cloned into the pRK172 bacterial expression vector for inducible protein 
expression.  Protein was expressed in BL21 (DE3) RIL E. coli cells.  Bacteria was grown in 
lysogeny broth, ampicillin was added, and when an optical density (OD) of 1.0 was reached, 
protein expression was induced with isopropyl-β-D-thiogalactopyranoside at a final 
concentration of 1.0 mM.  After continued growth for 2 hours, bacterial cultures were then 
centrifuged at 5,000 rpm for 15 minutes, and pellets were immediately frozen at -80°C.  Pellets 
were resuspended in a high salt RAB (Reassembly) buffer, pH 7.0 [0.1 M MES, 1 mM EGTA, 
0.5 mM MgSO4, 750 mM NaCl, 20 mM NaF, 0.1 mM phenylmethylsulfonyl fluoride (PMSF), 
0.1% protease inhibitor cocktail (L-1-tosylamide-2-phenylethylchloromethyl, N-tosyl-L-lysine 
chloromethyl ketone, leupeptin, pepstatin, and soybean trypsin inhibitor, each at 1 µg/ml)].  This 
resuspension was homogenized, boiled, and centrifuged at 100,000 x g for 30 minutes.  The 
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resulting supernatant, with addition of 0.1 mM PMSF and 0.1% protease inhibitor cocktail, was 
dialyzed against FPLC buffer, pH 6.5 [20 mM piperazine-N,N’-bis(ethanesulfonic acid), 10 mM 
NaCl, 1 mM EGTA, 1 mM MgSO4, 0.1 mM PMSF and 2 mM DTT].  After overnight dialysis, 
the contents of the dialysis was passed through a HiTrap sulfopropyl sepharose high performance 
cation exchange column (GE) attached to an ÄKTA Pure chromatography system equilibrated in 
FLPC buffer.  Fractions were eluted over a 0 – 0.4 M NaCl gradient.  Portions of the fractions 
were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and 
stained with Coomassie Blue R-250.  Fractions containing tau protein were subsequently pooled.  
The FPLC buffer present in pooled tau protein fractions was exchanged for 100 mM Sodium 
Acetate (pH 7.0), and protein was concentrated using Amicon Ultra centrifugal filter devices 
(Millipore Corporation, Billerica, MA).  Resultant protein concentration was determined using 
the bicinchoninic acid assay kit (Thermo Scientific Pierce). 
 
Tau Fibril Reactions. For sedimentation analysis, Thioflavin T, and negative stain electron 
microscopy, a concentration of 10 μM tau-K18 was incubated without agitation at 37°C with 10 
μM heparin (Sigma) and 2 mM dithiothreitol (DTT) in a 100 mM sodium acetate buffer (pH 
7.0).  Tau-T40 incubations were performed in a similar fashion, but used 15 μM tau-T40 / 15 μM 
heparin.  Fibril reactions for circular dichroism and cell seeding assay used 20 μM tau-K18 / 20 
μM heparin.  In the methylene blue sedimentation experiments, a fibril reaction mixture with 20 
μM tau-K18 and 40 μM Methylene Blue (Sigma) was held on ice for 5 minutes prior to adding 
heparin to a final concentration of 20 μM. 
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Sedimentation Analysis by SDS-PAGE. Tau fibril reactions were centrifuged at 21,100 x g for 
30 min at 4°C to create supernatant and pellet fractions.  The pellet fraction was resuspended in 
1X sample buffer and 100 mM DTT and an equal mass of supernatant was mixed with 6X 
sample buffer and 100 mM DTT.  Equal mass supernatant and pellet fractions for various 
reaction times were separated by SDS-PAGE followed by Coomassie Blue R-250 staining to 
detect protein. 
 
Thioflavin T Fluorescence Assay. The Thioflavin T (ThT) signal of tau-K18 and tau-T40 fibril 
reactions at various reaction times was measured at 430 nm (excitation) and 500 nm (emission) 
in a 10 μM ThT solution using a FLUOstar Omega microplate reader (BMG LABTECH, 
Germany).  Into each well, 5-15 uL of protein and 140-150 uL of 10 uM Thioflavin solution was 
added.  The plate was shaken briefly in the plate reader, and then the measurements were 
performed. 
 
Negative Staining Electron Microscopy. Five microliters of 10 μM K18 tau fibril reactions 
were placed on 400 mesh Formvar/Carbon film-coated copper grids (Ted Pella, Inc.) for 5 min, 
quickly washed with water two times, and then stained with 2% uranyl acetate for 30 seconds.  A 
LEO EM910 transmission electron microscope (Carl Zeiss Microscopy) at an acceleration 
voltage of 80 kV was used to visualize the fibrils.  The camera used was an Orius SC1000 CCD 
Camera, 2672 X 4008 pixels (11 megapixels) and Digital Micrograph version 2.3 software was 
used to acquire the images (Gatan, Inc.). 
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Circular Dichroism. Circular dichroism measurements were performed with a ChirascanTM 
circular dichroism spectrometer (Applied Photophysics Ltd, United Kingdom) using a cuvette 
with a 0.10 cm path length.  Circular dichroism data was collected from 190 nm to 250 nm at 0.5 
nm intervals.  For the 0-hour time point, K18 monomer at 20 µM in 100 mM sodium acetate 
buffer was dialyzed overnight against the CD buffer [10 mM potassium phosphate, 100 mM 
potassium fluoride pH 7.0].  For the 1-hour time point, CD spectra were generated using 20 µM 
tau fibril reaction pellet fractions resuspended in CD buffer. 
 
Tubulin Polymerization Assay. Tubulin polymerization at 37°C was monitored via Absorbance 
readings at 350 nm using a FLUOstar Omega microplate reader (BMG LABTECH, Germany).  
Polymerization reactions contained 2 mM GTP (Sigma), 55 µM purified tubulin (Cytoskeleton), 
and 40 µM purified K18 protein (or no tau in case of control).  The reactions were carried out in 
PEM buffer [80 mM piperazine-N,N’-bis(ethanesulfonic acid) pH 6.9, 0.5 mM EGTA, 2 mM 
MgCl2 hexahydrate].  Absorbance data was collected at 1 minute intervals for 45 minutes. 
 
Tau-K18 Fibril Seeding Assay in QBI-293 cells. QBI-293 cells transfected with indicated tau-
T40 plasmids were transduced with indicated tau-K18 fibrils or no fibril control.  Each fibril 
treated well of the 6-well plate received a target of 6 µg of fibrils.  Fibril pellets were generated 
by centrifuging a portion of a tau-K18 fibril reaction (volume calculated to provide 6 µg per 
treatment with extra volume for any loss during sonication) for 30 minutes at 4°C.  After 
supernatant was removed, pellets were resuspended in OptiMEM (165 µL) and then sonicated 30 
times.  No fibril controls were just OptiMEM.  The sonicated fibrils (or no fibril controls) (150 
µL) were then added to OptiMEM plus Lipofectamine2000 (144-150 µL OptiMEM; 6 µL 
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Lipofectamine2000) and allowed to stand for 20 minutes at room temperature.  This fibril-
Lipofectamine mixture (250 µL) was added drop-wise to the transfected cells.  After an 
overnight incubation, cell culture media was replaced with fresh, full DMEM media.  Cells were 
lysed 44-48 hours after fibril addition.  They were scraped on ice into 200 µL Triton X-100 lysis 
buffer [1% Triton X-100, 150 mM NaCl, 50 mM Tris pH 7.6] supplemented with deacetylase, 
phosphatase and protease inhibitors (3 µM Trichostatin A (TSA), 10 mM Nicotinamide (NCA), 
1 mM NaF; 1 mM sodium orthovanadate; 1 mM PMSF; and L-1-tosylamide-2-
phenylethylchloromethyl, N-tosyl-L-lysine chloromethyl ketone, leupeptin, pepstatin, and 
soybean trypsin inhibitor, each at 1 µg/ml).  The samples were sonicated 20 times and 
centrifuged at 21,100 x g for 30 minutes at 4°C.  The supernatant was reserved as the Triton-
soluble fraction.  A second 200 µL Triton X-100 extraction was performed on the pellet using 
the same parameters as the first Triton X-100 extraction.  The last extraction of the pellet was 
performed using 65 µL SDS lysis buffer [1% SDS, 150 mM NaCl, 50 mM Tris pH 7.6] 
supplemented with the same deacetylase, phosphatase, and protease inhibitors as the Triton X-
100 lysis buffer.  The samples were sonicated 20 times and centrifuged at 21,100 x g for 30 
minutes at room temperature.  The supernatant from this was reserved as the SDS-soluble 
fraction. 
 
Tau-K18 Fibril Seeding Assay in primary cortical neurons. Primary cortical neurons were 
harvested from embryos (E15-E17) of a transgenic mouse line expressing mutant P301S-K280Q 
human tau.  On DIV5, the neuron seeding assay began.  Each fibril treated well of the 6-well 
plate received a target of 3.75 µg of fibrils.  Fibril treatments were prepared by mixing fibril 
reaction with 1X DPBS and then sonicating this mixture 60 times.  There were two types of no 
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fibril control treatments: (1) wells with no treatment at all and (2) wells treated with fibril 
reaction sodium acetate buffer plus 1X DPBS.  Cells were lysed at DIV15.  They were scraped 
on ice into 300 µL Triton X-100 lysis buffer [1% Triton X-100, 150 mM NaCl, 50 mM Tris pH 
7.6] supplemented with deacetylase, phosphatase and protease inhibitors (3 µM Trichostatin A 
(TSA), 10 mM Nicotinamide (NCA), 1 mM NaF; 1 mM sodium orthovanadate; 1 mM PMSF; 
and L-1-tosylamide-2-phenylethylchloromethyl, N-tosyl-L-lysine chloromethyl ketone, 
leupeptin, pepstatin, and soybean trypsin inhibitor, each at 1 µg/ml).  The samples were 
sonicated 20 times and centrifuged at 21,100 x g for 30 minutes at 4°C.  The supernatant was 
reserved as the Triton-soluble fraction.  A second 300 µL Triton X-100 extraction was performed 
on the pellet using the same parameters as the first Triton X-100 extraction.  The last extraction 
of the pellet was performed using 80 µL SDS lysis buffer [1% SDS, 150 mM NaCl, 50 mM Tris 
pH 7.6] supplemented with the same deacetylase, phosphatase, and protease inhibitors as the 
Triton X-100 lysis buffer.  The samples were sonicated 20 times and centrifuged at 21,100 x g 
for 30 minutes at room temperature.  The supernatant from this was reserved as the SDS-soluble 
fraction. 
 
Western blot. Cell lysates were resolved via SDS-PAGE (10% for tau-T40 and 15% for tau-
K18), transferred to nitrocellulose membrane (Biorad), and blocking was performed in 2% non-
fat milk in 1X Tris-buffered saline for 30 minutes.  Membranes were incubated with primary 
antibody overnight at 4°C, followed by a 1-hour room temperature incubation with HRP-
conjugated anti-mouse or anti-rabbit secondary antibodies (1:1000).  The following primary 
antibodies were used: pSer202/pThr205-tau (AT8, 1:1000, Thermo Fisher Scientific, MN1020), 
pSer396-tau (1:1000, Thermo Fisher Scientific, 44-752G), tau T46 (1:1000, Thermo Fisher 
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Scientific, 13-6400), tau-1 (1:1000, Millipore, MAB3420), and GAPDH (1:1000, Santa Cruz 
Biotechnology, sc-25778). 
 
Transduction of tau fibrils into PS19 mice. PS19 mice were generated using a cDNA encoding 
the human 1N4R tau isoform with the P301S tau gene mutation that is pathogenic for familial 
frontotemporal dementia (FTD) driven by the murine prion protein promoter (Yoshiyama et al, 
2007).  Fibril treatments were prepared by resuspending pellets from tau-K18 fibril reactions 
(K280Q and P301L) in 1X DPBS and then sonicating this mixture 60 times.  The no fibril 
control was 1X DPBS alone.  All mouse experiments were performed in accordance with 
protocols approved by the Institutional Animal Care and Use Committee of the University of 
North Carolina at Chapel Hill.  After deeply anesthetizing 6-month-old PS19 mice of either sex 
with Avertin, they were immobilized in a stereotaxic frame (David Kopf Instruments).  The mice 
were separately injected into hippocampus (bregma, -2.5 mm; lateral,+2 mm; and depth,-1.8 
mm) with the following: (1) K18 K280Q recombinant tau fibrils (1 µg/µL); (2) K18 P301L 
recombinant tau fibrils (1 µg/µL); or (3) DPBS vehicle in a final volume of 5 µL.  The total 
volume injected per site was 5 µL for all mice.  Three mice were injected per experimental 
condition. 
 
Histology and immunohistochemistry. At 1 month post-injection, all injected PS19 mice were 
deeply anesthetized, transcardially perfused with 0.9% saline, followed by 4% paraformaldehyde 
(PFA), after which the brains were removed, bisected, and postfixed for 48 hours by immersion 
in 4% PFA, and then thoroughly rinsed in leaching buffer [50 mM Tris-150 mM NaCl, pH 7.6].  
The brains were then embedded in paraffin blocks from which 5-µm-thick sagittal sections were 
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cut through the brain for immunohistochemistry (IHC).  Immunohistochemical analysis of AT8 
was performed on paraffin specimens using Thermo Fisher Phospho-PHF tau (AT8) Cat # 
MN1020.  Antigen retrieval was performed with citrate buffer (pH 6.0) for 72 minutes at 100°C 
and then blocked with a protein block for 1 hour at room temperature.  The samples were given a 
peroxidase block for 8 minutes at room temperature and incubated in the primary antibody 
(1:500) for 1 hour at room temperature, followed by the secondary antibody (1:500; Anti-IgG1 + 
IgG2a + IgG3 antibody, Abcam Cat # 133469) for 1 hour at room temperature, and then the 
tertiary antibody (Ventana Omap OmniMap anti Rat HRP, 760-4457, Ready to Use) for 32 
minutes at room temperature.  The samples were treated with 3,3’-diaminobenzidine (DAB), 
Hematoxylin II for 12 minutes, and then Bluing Reagent for 4 minutes.  The slide staining was 
performed using Ventana’s Discovery Ultra Automated IHC staining system. 
 
Statistical analysis. Comparison between two groups was analyzed using two-tailed, unpaired t-
test. Significance is presented with *, **, and *** corresponding to p < 0.05, p < 0.01, and p < 
0.001, respectively.  Error bars represent the standard deviation (s.d.) of the mean.  Statistical 
analysis was performed using GraphPad Prism software. 
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Results: 
Mimicking tau acetylation of K280 and K280/K281 impairs tubulin polymerization 
 
 In a study from 2011 (Cohen et al., 2011), mass spectrometry was used to identify sites of 
full-length tau acetylation in cultured cells.  HEK-293 cells stably expressing tau-T40 were 
transfected with CBP, and then tau was immunoprecipitated and subjected to mass spectrometry.  
The sites reported to be acetylated were K163, K280, K281, and K369 (Cohen et al., 2011).  Of 
these four lysine residues, the K280 and K281 residues already have some documented 
importance to tau-MT interactions.  Previous data indicated these lysines made contact and 
stabilized charge interactions between tau and MTs (Goode and Feinstein, 1994).  More recent 
mass spectrometry data also indicates that these two lysine residues can be doubly acetylated in 
293 cells.  Reversible acetylation of these lysines results in neutralization of the normally 
positive charge of lysine when at pH 7.0.  Our hypothesis is that acetylation of these tau lysine 
residues known to contact MTs would impair MT stability.  A loss of MT stability driven by tau 
would imply a loss of tau function. 
 Therefore, we tested the effects of single or double K280/K281 acetylation mimic 
(KQ) or non-acetylation mimic (KR) mutations on MT assembly functions.  The lysine to 
glutamine mutation mimics the lysine acetylation event positive charge neutralization.  The 
effects of tau were assessed using an in vitro tubulin polymerization assay, with tubulin 
polymerization being a surrogate for MT assembly (Fig. 1).  This assay was performed using 
recombinant tau-K18 protein, either wild type or one of the mutants that mimics acetylation or 
the prevention of acetylation.  Since the tau-K18 construct contains tau’s microtubule binding 
region, it is a powerful tool to assess the tau-MT interactions.  The MTBR also is an integral 
component of tau NFT pathology.  The data from the assay indicates that tau has a strong effect 
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on tubulin polymerization.  When no tau was placed into the reaction mixture, the tubulin did not 
polymerize.  When WT tau was added, tubulin polymerization proceeded as expected.  Both 
single (K280Q) and double K280/K281 acetylation mimic (K280Q/K281Q, 2KQ) hindered 
tubulin polymerization.  The K280Q mutant reduced tubulin polymerization by almost half (Fig. 
1a) and the double mutant (K280Q/K281Q, 2KQ) almost completely prevented tubulin 
polymerization (Fig. 1b), similar to the no tau control.  In contrast, tau constructs that contain 
KR mutations to model lysines that cannot be acetylated produced tubulin polymerization that 
was comparable (K280R, Fig. 1a) or enhanced (K280R/K281R, 2KR, Fig. 1b) relative to WT 
tau.  Importantly, despite the large variability with the K280R mutant, there is still a significant 
difference between the K280R and K280Q mutants (p < 0.0001).  More replicates of K280R 
could be performed to try to reduce the standard deviation observed in the experiment.  These 
results indicate that acetylated K280 or double acetylated K280/K281 do impair MT stability, 
and produce a loss of what is considered to be normal tau function. 
 
Mimicking tau acetylation of K280 promotes tau aggregation in vitro 
 Previous data generated using IHC and immunofluorescence techniques indicated that tau 
acetylated at the K280 residue is a robust marker of tau aggregation in AD brain (Cohen et al., 
2011).  That same study also indicated that a fully acetylated tau could induce tau aggregation in 
vitro.  However, it remained unclear whether the acetylation of K280 was directly causing the 
tau aggregation observed in the AD brain.  To further evaluate the direct role that acetylation of 
K280 plays in AD, we tested whether the acetylation mimic, K280Q mutation, could promote tau 
aggregation.  We started by running tau fibrillization reactions, and then used the reaction 
products to perform different assays to assess the degree to which tau had fibrillized/aggregated. 
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We first performed the tau-K18 fibrillization reactions without heparin, a polyanionic 
factor often used in these reactions to induce and expedite aggregation.  The initial non-heparin 
fibril reactions and subsequent sedimentation assay and electron microscopy was a success (Fig. 
2).  The sedimentation assay begins with a centrifugation step that allows for isolation of a 
supernatant tau fraction containing largely soluble tau, and a pelleted tau fraction which largely 
contains tau fibrils.  After isolating the two fractions, they are resolved by SDS-PAGE and 
stained with Coomassie Blue (Fig. 2a-d).  As anticipated, the WT tau-K18 never transitioned to 
the pellet fraction over the 4 day time course.  We also used a tau mutation, P301L, that we 
anticipated would be driven into the pellet fraction since the mutation is known to be an 
aggregation-prone mutation associated with frontotemporal dementia.  Results for P301L mutant 
tau-K18 also met expectations, with tau transitioning to the pellet fraction between 8 hours and 1 
day (Fig. 2b).  Our results on K280Q, the acetylation mimic, are somewhere on the spectrum 
between WT tau and P301L tau, showing a slight transition to the pellet fraction starting at 8 
hours and growing by 1-2 days, and finally beginning to shift completely to the pellet fraction at 
~4 days (Fig. 2c,d).  We were also able to confirm we had robust K280Q tau fibrillization at 2 
days via electron microscopy (Fig 2e).  While this data does indicate that K280Q tau-K18 has the 
propensity to form fibrils, compared to WT tau-K18, we were unable to generate these same 
results on a consistent basis.  This lack of consistency was unfortunate because the presence of 
heparin, at least the type we used, appeared to be problematic in neuron fibril treatment 
experiments. 
We then shifted to fibrillization reactions that included an equimolar ratio of tau to 
heparin (Fig. 3).  As anticipated, the WT tau-K18 was slow to transition to the pellet fraction, 
showing an almost full transition to the pellet at 8 hours (Fig. 3a).  In contrast, the P301L mutant 
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tau-K18 was almost fully pelleted at 1 hour (Fig. 3b).  Most importantly, the K280Q mutant tau-
K18 also was fully pelleted by 1 hour (Fig. 3c), while the K280R mutant behaved similarly to 
WT tau-K18 (Fig. 3d).  To confirm that K280Q was promoting tau aggregation, we used a 
Thioflavin T (ThT) fluorescence assay to detect amyloid structure over a time course of 
fibrillization reactions.  Our results mirrored those of the sedimentation assay.  The ThT signal 
for both WT and K280R tau-K18 were low until 8 hours, at which time it rose slightly (Fig. 3e). 
In contrast, the ThT signal for both P301L and K280Q tau-K18 sharply increased (almost 5-6 
fold that of WT and K280R) at 1 hour and held this signal level over the 8-hour time course (Fig. 
3e). 
These tau-K18 results were promising, and we decided to test if the K280Q mutation in 
full-length tau would have a similar effect on tau aggregation.  In this next set of fibrillization 
reactions, we used the full-length tau-T40 isoform.  We observed that the aggregation kinetics 
for K280Q is similar to P301L and is accelerated compared to WT tau-T40, showing increased 
pellet fraction at 1 day (Fig 4a-c).  The sedimentation assay appears to indicate that the 
aggregation dynamics of WT tau-T40 catches up to K280Q at 2 days for 1 of the 2 independent 
fibril reactions.  This accelerated protein aggregation behavior is also mirrored in the ThT results 
(Fig. 4d), but the data also indicates amyloid structure in the P301L fibril reactions is by far the 
most robust. 
To further confirm the acceleration of fibril formation, we next performed negative 
staining electron microscopy (EM) of the WT tau-K18, K280Q tau-K18, and P301L tau-K18 
fibrillization reactions.  Consistent with the sedimentation and ThT results, we observed very 
few WT tau-K18 fibrils at the 2-hour time point, while for K280Q and P301L we observed 
numerous, dense fibril networks (Fig. 5a, top row).  We also imaged fibrillization reactions at the 
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4-hour time point, and this data also showed a paucity of WT fibrils while the K280Q and P301L 
fibrils were still in numerous, dense networks (Fig. 5b, bottom row). 
The tau pathology observed in AD are rich is β-sheet secondary structure (Cohen et al., 
2011) and this pathology is also positive for ac-K280 (Cohen et al., 2011).  We decided to test if 
K280Q fibrils also were rich in β-sheet secondary structure using circular dichroism (CD), and 
secondarily whether CD could be used as another measure of the kinetics of tau aggregation.  CD 
is a spectroscopic technique that detects differences between left and right-handed polarized 
light, and it is a helpful tool in predicting the secondary structure of protein molecules.  The 
technique can distinguish whether a protein has adopted a conformation that is largely (1) 
disordered/random coil or contains (2) α-helix or (3) β-sheet structure.  CD has previously been 
used to assess the secondary structure of tau protein (Kumar et al., 2014).  With our fibrillization 
reactions, we expected to see a transition of tau secondary structure from random coil (0-hour 
time point) to β-sheet structure (1-hour pellet fraction time point).  With a shift in minimum 
absorbance to around 215 nm by 1 hour, we observed that both K280Q and P301L pellet 
fractions had CD profiles that indicate a transition to β-sheet structure (Fig. 6b,c).  Furthermore, 
this minimum wavelength shift is consistent with other reports for aggregate-prone fibrils 
(Barghorn et al., 2000; von Bergen et al., 2000).  By 1 hour, neither WT (Fig. 6a) or K280R (Fig. 
6d) pellet fractions displayed as strong a shift to β-sheet structure as K280Q, which is in 
agreement with the delayed kinetics indicated by the sedimentation and ThT assays.  However, 
there is a possibility that the tau in the supernatant fractions for WT and K280R at these time 
points are still β-sheet.  We did not analyze the supernatant fractions for these particular time 
points, but the one WT 4 h supernatant profile we did analyze indicated the presence of β-sheet 
structure. Thus, the presence of β−sheet structure in a given pellet fraction is not too striking; it 
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could just be the product of the faster kinetics of the fibril reaction.  A more distinct difference 
between WT and K280Q or P301L could be achieved with a lower concentration of tau in the 
fibrillization reaction used for circular dichroism.  At the 20 µM tau concentration used, the WT 
is seemingly catching up to K280Q quicker than the 10 µM concentrations used in the 
sedimentation assays, ThT, and EM.  Taken together, these results indicate that a single K280Q 
mutation is sufficient to accelerate tau aggregation in vitro. 
 
Testing the effect of methylene blue on tau solubility 
The results above indicated that acetylation of K280 accelerates tau aggregation relative 
to WT tau.  Both academic researchers and drug companies have invested in the notion that 
methylene blue (MB) and its derivatives can inhibit tau aggregation and have cognitive benefits 
in the context of neurodegenerative disease (Akoury et al., 2013; Congdon et al., 2012; Crowe et 
al., 2013; Hochgrafe et al., 2015; Hosokawa et al., 2012; Wischik et al, 2015).  Previous work 
using nuclear magnetic resonance (NMR) spectroscopic analysis indicated that MB causes NMR 
spectra signal location and intensity changes in tau’s MTBR tandem repeats 2 and 3 (Akoury et 
al., 2013).  Upon analysis of the spectral data of tau in the presence of MB, those authors 
targeted two cysteines of tau for mutational analysis (C291 and C322) (Akoury et al., 2013).  
After mutation of these two residues, the NMR spectra of tau with methylene blue reverted to an 
NMR spectrum that looked like tau by itself (Akoury et al., 2013).  This and some additional 
work in the presence of DTT helped to indicate that MB was acting on tau by oxidizing at least 
these two tau cysteine residues (Akoury et al., 2013).  Another previous study looked at the 
shared properties of aminothienopyridazine compounds (ATPZs) and MB (Crowe et al., 2013).  
Like MB, the ATPZs also appear to act by oxidizing the same cysteine’s in tau.  The Crowe et al. 
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paper indicated that the oxidation of tau cysteines (i.e. C291, C322) would result in the inhibition 
of monomeric tau fibril formation when all four of tau’s microtubule-binding tandem repeats are 
present (4R-tau), but result in dimerization and high MW species formation when only tandem 
repeats 1, 3, and 4 are present (3R-tau). 
We decided to test what effect methylene blue has on WT and K280Q acetylation mimic 
tau solubility.  In my work, I used tau sedimentation assays to evaluate MB’s effects.  We pre-
incubated tau-K18 (MTBR fragment of 4R-tau) with the MB prior to starting the fibrillization 
reactions.  Initial studies starting at 2 hours of incubation showed that MB does not have much 
effect on reducing tau aggregation in this time frame.  The results also indicate that the presence 
of MB enhanced the presence of dimer and higher MW tau species for both WT and K280Q tau 
(Fig. 7a,b).  The formation of tau dimers by pre-oxidizing recombinant tau or exposure of tau to 
MB or an ATPZ compound has previously been reported for a 3R-tau fragment (Crowe et al., 
2013).  In contrast, in that same study, dimer formation was only reported for 4R-tau when one 
of the implicated tau cysteines were mutated (Crowe et al., 2013).  Furthermore, one of the 
earlier studies that tested the effects of methylene blue on tau also included data showing 
decreased monomeric full-length tau levels, but sharply increased levels of dimer and higher 
MW levels of tau (Taniguchi et al., 2005).  Since I used the tau-K18 4R-tau fragment, with no 
cysteine modification, it was somewhat surprising to observe dimers and higher MW species.  As 
we evaluated my results in tandem with our sedimentation assay results, we made the following 
conclusions to be used to inform subsequent studies: (1) MB could have an effect during the 
growth phase of the tau fibrils (i.e. earlier time points), (2) the effect of MB could be dependent 
on MB concentration and amount of pre-incubation time, and (3) the effect of MB might be 
sensitive to tau concentration and method of fibril reaction.  Another reason to try earlier time 
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points was that a previous study reported that giving MB prior to cognitive decline reduced 
insoluble tau in a mouse model (Hochgrafe et al., 2015).  However, in this same study gels were 
cut off above 80 kDa and were very bright so it is impossible to independently ascertain whether 
higher MW tau was present upon MB treatment.  In subsequent experiments, (1) earlier time 
points were added, (2) MB concentration and pre-incubation time before heparin was added was 
increased, (3) tau concentration was decreased, and (4) no agitation was used in the fibril 
reactions.  It is difficult to say what the clinical implications are of the observation of enhanced 
presence of dimer and high MW tau species upon MB treatment.  A potential concern related to 
the dimer and other high MW tau species formation is that some in the field have labeled 
oligomeric and other high molecular weight tau as potentially toxic (Ward et al., 2012).  
Additionally, even if it were true that MB caused higher MW species of tau only in 3R-tau 
(Crowe et al., 2013), this still negatively could impact AD patients, since 3R-tau is present in 
adult brain.  This data showing an increase in higher MW species of tau upon exposure to MB 
suggests that MB may be counterproductive in the treatment of tau aggregates in AD at more 
advanced disease states. 
 
Acetylation mimic tau fibrils promote full-length tau aberrant PTMs and insolubility 
The phenomena of tau spreading from cell to cell, and that insoluble forms of tau are able 
to induce soluble tau to become aberrantly phosphorylated, mis-folded, and aggregated in cell 
culture and in vivo has been previously described (Frost et al., 2009; Guo and Lee, 2011; Guo 
and Lee, 2013; Iba et al., 2013; Wu et al., 2016).  Intriguingly, there is indication that tau seeding 
also causes tau to become acetylated at the same lysine, K280, that marks tau lesions in AD 
brain.  Namely, when tau fibrils were injected into the hippocampus of P301S mutant transgenic 
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mice (PS19), there was a resultant appearance of acetylated K280 tau (Iba et al., 2013).  
However, evidence of whether tau acetylation induces this seeding process is unknown, and we 
had specific interest in testing whether K280 acetylation alone could drive the seeding process.  
Thus, we introduced WT, P301L, K280Q, and K280R tau-K18 fibrils into a QBI-293 cell culture 
system that transiently over-expressed P301L tau-T40, an aggregate-prone full-length construct 
of tau.  Tau fibrils were delivered to the cells via Lipofectamine reagent, which others have used 
for seeding experiments (Sanders et al., 2014), and the results were evaluated by immunoblotting 
soluble (Triton X-100 soluble) (Fig. 8a) and insoluble (SDS soluble) (Fig. 8b) extracted cell 
lysate fractions for phosphorylated tau.  Importantly, we did not see insoluble, phosphorylated 
tau (AT8) when cells were mock treated with Lipofectamine alone (Fig. 8b, lanes 1-2).  AT8 is 
used because it does not detect the tau-K18 fibrils and is a marker of AD tau pathology.  This no 
fibril data helps to validate that the seeding assay is working.  In contrast, when the QBI-293 
cells were exposed to accelerated 2 hour fibrillization reaction time points of K280Q and P301L 
tau fibrils, we observed tau in the insoluble fraction which was AT8 positive (p-S202/p-T205) 
(Fig. 8b, lanes 5-8).  While we also observed this insoluble tau with WT and K280R fibrils (Fig. 
8b, lanes 3-4 and 9-10), it is important to note that these fibrils were generated from much longer 
fibrillization reactions (24-hour time point).  These WT and K280R time points were chosen 
since the initial intent was to use time points that we had confidence would generate a complete 
pellet fraction.  However, subsequent experiments could be devised using matching 2-hour time 
points for these proteins.  It is very interesting that even WT and non-acetylation mimic fibrils 
can generate insoluble tau.  This data using tau-T40 P301L indicates that K280Q fibrils are 
sufficient to drive seeding of an aggregrate-prone version of full-length tau and that intriguingly, 
each fibril type, even WT and K280R, can induce the seeding phenomenon.  This hints that even 
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WT tau that becomes mis-folded in the brain can seed normally, soluble full-length tau. 
We also tested whether tau acetylation on K280 in full-length tau could induce a more 
severe seeding effect in comparison to unmodified WT or K280R full-length tau-T40.  Using the 
QBI-293 cells, we performed transfections with WT, K280Q, and K280R tau-T40 and then 
introduced K280Q fibrils into the cells.  After a 48-hour incubation with the fibrils, we observed 
that the K280Q mutant full length tau did result in a greater accumulation of phosphorylated tau 
(AT8) and total tau (T46 antibody) in the insoluble fraction, relative to cells transfected with 
both WT and K280R full length tau (Fig. 9b).  More work could be done to try to see whether the 
high MW AT8 positive bands in the insoluble fraction will migrate down the gel (Fig. 9b); this 
may be cross-reactivity with another protein homologous to this epitope of tau or just be 
detecting a large amount of protein that did not run out of the lane.  Indeed, these high MW 
bands also appeared in the uncropped version of insoluble AT8 in Fig. 8b, even in the no fibril 
treatment lanes.  The similar band pattern did not occur with insoluble T46, although insoluble 
T46 did show faint high MW bands in the three K280Q plasmid lanes (Fig. 9b).  Also interesting 
is the T46 band pattern in the soluble fraction wherein the three K280R plasmid lanes showed 
higher MW band to appear and both the K280Q and K280R plasmids caused more breakdown of 
tau than WT plasmid (Fig. 9a).  This initial experiment suggests that a full-length tau harboring 
acetylated K280, as modeled by an acetylation mimic, may create an environment that is more 
favorable for seeding of full-length tau to occur, relative to a tau that is unmodified or cannot 
become acetylated at the K280 residue.  This seeding experiments also suggest that acetylated 
tau is one of the species of tau that can participate in the cell-to-cell spread of tau pathology in 
AD.  Two subsequent experiments using WT, K280Q, and K280R tau-T40 were unable to 
reproduce this same result; one trial showed that K280Q tau-T40 was less than either K280R and 
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WT in the insoluble fraction and the other showed only that WT tau-T40 was insoluble and that 
K280Q and K280R were not. 
Since we had previous indication that using P301L tau-T40 would reliably drive the 
formation of insoluble (SDS-soluble) tau, we decided to test whether preventing K280 
acetylation would reduce the amount of insoluble tau.  Using the QBI-293 cells, we performed 
transfections with WT, K280R-P301L (KR-PL), and P301L tau-T40 and then introduced K280Q 
fibrils (and P301L fibrils) into the cells.  We planned to include a K280Q-P301L plasmid as 
well, but this plasmid did not generate tau protein in previous transfection experiments.  In the 
first trial of the experiment, we saw that all three plasmids produced insoluble AT8 and T46 tau 
when treated with either K280Q or P301L fibrils, but that P301L tau-T40 was trending higher 
than either WT and K280R-P301L tau (Fig. 10b,c).  In the soluble AT8 fraction, upon increasing 
the contrast setting, it should be noted that the KR-PL and P301L plasmids with K280Q fibril 
treatment had very faint bands of high MW signal that did not seem to run on the gel, with the 
KR-PL showing a bit higher signal than P301L (Fig. 10a).  The no fibril controls showed very 
minimal presence of insoluble tau, with only a very faint band visible for P301L plasmid using 
the T46 total tau antibody and tau-1 antibody detecting small amounts with each plasmid (Fig. 
10c,d).  This low amount of insoluble tau in the no fibril treatment is good because it indicates 
the seeding assay is working.  Tau-1 might have a higher affinity than T46 at the dilutions we 
used so that may be why it detects a small amount whereas T46 is not showing anything. 
Armed with these cell culture seeding results, we moved into seeding of tau transgenic 
mice (PS19 line) expressing an aggregrate-prone P301S mutant human tau.  This mouse line 
generates ThT-positive tau aggregates, has cognitive dysfunction, and behavioral deficits by 12-
15 months.  We used a mock treatment (PBS alone) and 2-hour time point K280Q fibrils and 
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P301L fibrils, and injected these treatments into the hippocampus of the mice.  We chose to 
perform this initial injection at 6 months of age since this is before the mouse develops mature 
tau pathology.  We removed and fixed the brains at one-month post-injection, again since this 
was still prior to formation of mature tau pathology known for this PS19 mouse line.  
Subsequently, we performed immunohistochemistry on brain slices using the AT8 phospho-tau 
antibody (Fig. 11).  We saw intense AT8 signal in the ipsilateral (injected) hippocampus of 1 of 
3 mice injected with K280Q fibrils, and there was less AT8 signal in the contralateral 
hippocampus indicative of seeding.  The other two mice injected with K280Q fibrils had less 
intense AT8 staining on the ipsilateral side relative to the contralateral side, but there might still 
be a trend.  Two of the three mice injected with P301L fibrils showed some hints of seeding on 
the ipsilateral side but one P301L fibril injected mouse did not show any signs of seeding.  In the 
PBS injected mice, the level of AT8 signal on the ipsilateral side look very similar to the two 
weak AT8 signal K280Q fibril injected mice, with PBS-1 contralateral even looking higher in 
intensity.  We would need to quantify staining intensity to adjudicate if there are any statistical 
significance differences.  Also, the non-injected side hippocampus was rotated out of plane (or 
disfigured) in two of the PBS control brains.  Additional serial sectioning could determine if 
more information can be gleaned from these two contralateral PBS control hippocampus.  
Additional in vivo injection experiments are necessary to help make the case that K280Q is 
inducing seeding.  Along with the preceding QBI-293 experiments, this initial in vivo experiment 
hints that K280Q fibrils are sufficient to induce the conversion of aggregrate-prone full length 
tau to an aberrantly phosphorylated, aggregated form of tau. 
In addition to the seeding experiments in PS19 mice, we have also been working on some 
of the early characterization of a mouse harboring the acetylation mimic, K280Q, tau mutation.  
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As stated previously, we injected tau fibrils into a line of mice expressing P301S, an aggregate-
prone tau mutation linked to familial dementia.  To study the effect of the K280Q tau mutation, 
we generated mice that express both a P301S and a K280Q mutation (referred to as PS-KQ). 
We began characterizing this line by evaluating its seeding potential and tau protein 
expression using primary neuron culture from these PS-KQ mutant mice.  We performed two 
seeding experiments with the PS-KQ mutant mice using cortical neurons, and I have performed 
cursory biochemical characterization from the first seeding experiment.  We seeded the neurons 
at DIV5 with tau fibrils grown for the specified time: WT (8 hours), P301L (2 hours), and 
K280Q (4 hours).  At DIV15, we harvested the neurons and separated them into a soluble and 
insoluble fraction, like we did for the QBI-293 cell seeding experiments.  Others have reported 
being able to run their fibril treatments for 18 days, but we ended our treatments after 10-14 days 
of fibril treatment since we observed swelling of the neuron processes.  We attributed this 
swelling to residual high molecular weight heparin species in the fibril treatments, despite having 
centrifuged and re-suspended the tau fibrils in sodium acetate buffer.  Neurons treated with the 
sodium acetate buffer alone were not observed to have the swelling processes.  Interestingly, I 
saw what appeared to be insoluble, potentially endogenous mouse phospho-S396 tau in these 
neuron cultures, even in the non-fibril treated condition (Fig. 12a).  The S396 residue is one of 
the residues known to be aberrantly phosphorylated in AD.  If indeed it is endogenous mouse 
tau, seeing insoluble p-S396 is paradoxical since it is thought that endogenous mouse tau is not 
normally insoluble.  This caused me to ask if this was unique to our PS-KQ mouse line. 
I ran another immunoblot containing lanes of non-fibril treated CD-1 mouse, P301S 
mutant tau, and PS-KQ mutant tau cell lysate, with the CD-1 mouse constituting our wild-type 
tau condition.  We again observed the same double band pattern for phospho-S396 in the 
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insoluble tau fraction (Fig. 12b).  It showed up for the CD-1 (faintly) and P301S line (strongly), 
but there was no detection for the PS-KQ line of mice.  This seems to indicate that the first blot 
containing all PS-KQ treatments is incorrect or at least misleading.  Another observation was a 
higher MW band positive for pS396 for P301S mice (Fig. 12b, top band, lane 2) that is not 
present for CD-1 or PS-KQ mice.  This higher MW band could represent more mutant human tau 
being expressed or tau being phosphorylated to a greater extent in the P301S line.  During further 
characterization of the PS-KQ line, we may find that the tau (endogenous and human) is hypo-
phosphorylated at this residue.  An attempt at an AT8 blot, like we had done for the QBI-293 
assays, was inconclusive.  The blots of CD-1, P301S, PS-KQ non-fibril treated lysate showed no 
bands for either soluble or insoluble fractions.  I expected to see bands for the P301S line in both 
soluble and insoluble fractions, given my knowledge of what IHC for AT8 looks like for this line 
of mice.  
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Discussion 
Using the previous work showing the association of tau K280 and K281 with MTs as a 
springboard (Goode and Feinstein, 1994), this data now adds evidence that the acetylation of 
K280 and double acetylation of K280/K281 alters tau’s MT assembly property (Fig. 1), and in 
the case of K280 is sufficient to accelerate tau aggregation relative to WT tau (Fig. 2-6).  We 
also began to investigate the effect MB has on tau’s solubility (Fig. 7).  Due to the appearance of 
dimers and higher MW tau and lack of aggregation inhibition in our initial experiment, which is 
similar to previously published results using full-length tau (Taniguchi et al., 2005), more tests 
are needed to identify MB’s true effect on tau solubility.  We also have an indication that tau 
K280 acetylation alters the pattern of PTMs on the rest of tau via our early seeding assay work 
(Fig. 8-11).  Our seeding data in QBI-293 cells suggests that the acetylation of K280, which is 
observed in AD, could potentially set off a pathogenic domino effect of normally soluble tau 
becoming aberrantly phosphorylated and aggregated (Fig. 8-10).  This finding adds to the 
evidence implicating acetylation of K280 in the cell to cell transmission of tau pathology.  Both 
K280Q and aggregate-prone P301L fibrils from the same fibrillization time point appear to both 
act to drive normally soluble tau to an aberrantly phosphorylated, insoluble state (Fig. 8, 10).  
Intriguingly, in the experiment using WT, K280R-P301L, and P301L tau-T40 plasmids, it also 
appears that the K280Q fibrils have a more pronounced effect than the P301L fibrils (Fig. 10).  
At this concentration of fibril reaction, the thioflavin T signal for K280Q 2 hour fibrils was 2-
fold higher than the P301L 2 hour fibrils.  This may be the reason for this increased effect to 
drive the tau into the insoluble fraction.  Replication would be needed to confirm this, since the 
experiment where WT 24 hour, K280Q 2 hour, P301L 2 hour, and K280R 24 hour fibrils were 
used did not show as striking a difference between K280Q and P301L 2 hour fibrils (Fig. 8). 
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Prior to discovering that the K280 residue was acetylated in brains containing tauopathy, 
all the field knew that linked this residue to disease was a genetic deletion of K280 (∆K280) seen 
in FTDP-17 patients and a single case of AD (Momeni et al., 2009).  At face value, the 
acetylation of K280 and its deletion leading to neurodegenerative disease appear to be at odds.  
One unifying proposal is that the acetylation of K280 or its deletion, ∆K280, can bring about loss 
of normal tau function to stabilize microtubules and promote the formation of tau aggregates.  
Both events reduce the positive charge in that region of the protein.  We also know that K280 
and K281 residues mediate MT interactions (Goode and Feinstein, 1994).  The shared 
phenotypes between acetylated K280 and ∆K280, and the lack of proven association of causal 
tau mutations with AD, allows for the possibly that acetylation of K280 is one contributor to the 
aggregation of wild-type tau in AD. 
In the lab’s future study of K280 acetylation, it would be interesting to repeat the fibril 
seeding experiments using primary neuron cultures and in vivo with mice expressing human WT 
tau, mice expressing the P301S mutation (PS19 line), and mice expressing both the P301S and 
K280Q mutations.  My initial attempts at seeding in primary neuron cultures were unable to 
replicate the success of other labs (Guo and Lee, 2013) in that the western blots did not show any 
increase in insoluble human tau.  One of the avenues to take to increase the likelihood of success 
of these seeding experiments, which rely on length of time neurons are exposed to tau fibrils, 
would be to switch over to low molecular weight heparin to induce tau fibril growth.  The 
heparin we used caused the neuron processes to swell as early as 3 days after exposure to the 
fibrils.  I also attempted to centrifuge the fibrils and re-suspend them in a buffer not containing 
heparin, but this just delayed the swelling effect for a few days. 
Beyond the seeding paradigm, we should also continue characterizing the neurons and 
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tissue from PS-KQ mice.  My observations when imaging tissues from one line of these mice 
indicated a lack of AT8 signal in all PS-KQ mice examined and a low level of total tau (tau 12) 
signal in some mice while other mice largely lacked tau 12.  The IHC signal intensity also was 
reduced for PS-KQ mice compared to slices of PS19 tissue on the same slide. 
It is possible that the additional K280Q mutation is serving to dephosphorylate the AT8 
epitope.  The observations from our early IHC work somewhat correlated with my early 
biochemical characterization of PS-KQ primary neuron cultures, where there was a lack of AT8 
in the insoluble fraction in the blots I have performed, resulting in blank blots, even after a more 
sensitive enhanced chemiluminescence (ECL) incubation.  Further attempts at the AT8 western 
will need to include a known positive control for AT8, such as a Triton fraction from one of the 
QBI-293 experiments.  Furthermore, in a blot for pS396 (Fig. 12b), the lack of a slightly higher 
MW band just above the two darker bands may also indicate a hypo-phosphorylation at this other 
site in our PS-KQ line, since the established P301S line showed this slightly higher MW band. 
Performing additional IHC characterization on all of our PS-KQ lines of mice and adding 
appropriate size cohorts of nTg mice and mice expressing human WT tau would provide an even 
stronger case for these observations.  In our three PS-KQ mouse lines, we should also confirm 
expression of the human tau in brain regions of interest (cortex and hippocampus) by western 
blot and compare this to age-matched human WT and P301S mutant tau transgenic controls. 
These mice containing the K280Q mutation could serve as a great platform to study the 
effects of a single-site tau acetylation.  Another group has generated a mouse harboring a double 
mutation at K274/K281, and compared their mouse to a line expressing human WT tau to assess 
phenotypes and possible mechanisms that have relevance to AD (Sohn et al., 2016; Tracy et al., 
2016).  Following their example, we could look at whether our K280Q mutation drives the 
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endogenous tau and transgenic human tau into somatodendritic compartments of the cell, a 
translocation which is thought to be part of the reason why tau becomes toxic in AD.  Similarly, 
we could also examine the interplay between this modeling of acetylation and tau-MT 
interactions, since their group saw some MT dynamics effects with the acetylation mimicry 
(Sohn et al., 2016).  Lastly, we could study how our K280Q mutation impacts tau’s pattern of 
phosphorylation, propensity to aggregate, synaptic function, and overall mouse behavioral 
phenotypes. 
By expressing human tau in our mice, one critique might be that we are introducing 
another variable into the model.  One way to address this is to continue to compare our results to 
nTg mice and mice expressing human WT tau.  Outside of our approach, no way yet exists to 
target and keep single tau lysines acetylated in vivo since endogenous deacetylases (i.e. HDAC6) 
would act on the tau.  Furthermore, knocking deacetylases down or out of a living organism 
would introduce even more variables since these enzymes act on a myriad of proteins.  Other 
alternate approaches being considered in our lab are generating mice that over-express mutant 
K280Q human tau by itself or that express K280Q endogenous mouse tau.  Previous attempts of 
the latter approach have been made with the aggregate-prone frontotemporal dementia tau 
mutation, P301L (Gilley et al., 2012).  However, with both these acetylation mimic methods, we 
would still have to contend with the critique that the acetylation mimic approach keeps the tau in 
a permanently charge neutral state on that lysine. 
Another future direction would be to examine whether there is a synergy between K280 
and K281 acetylation using cell culture and in vivo models since our results indicate an almost 
complete loss of MT assembly when both lysines are mutated to acetylation-mimicking 
glutamines.  We could extend our MT assembly experiment by performing a cell-based tau-MT 
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binding assay, and we could also generate double acetylation mimic K280Q/K281Q mice.  
Continued biochemical characterization in cell culture and in AD brain to determine 
stoichiometry of acetylation of tau lysines (especially K280 and K281), and to discover novel 
sites of acetylation would also be important contributions to the field. 
Within the context of this work, our modeling of K280 and K281 acetylation, both in 
vitro and in vivo has further implicated the acetylation of these residues, and perhaps the local 
charge character of this region of tau, in the loss of tau function, acceleration of tau aggregation, 
and propagation of tau pathology.  Our results begin to tie K280 acetylation to the initiation, as 
well as propagation, of AD tau pathology and merit further study of the effects of acetylation of 
this residue as well as ways in which to mitigate these effects pharmacologically.  It also 
indicates that acetylation of K281, in tandem with K280, seems to worsen the pathological effect 
of tau.  Looking beyond K280 and K281, there may be other sites of tau more critical than K280 
and K281 to both tau’s physiological function and pathological activation.  Tau contains over 25 
lysines that are subject to acetylation (Cook et al., 2014a), hinting that this PTM is likely an 
active regulator of tau in vivo, similar to tau phosphorylation.  This and other work has also 
uncovered some of the interplay between tau acetylation and phosphorylation (Fig 8-11, Cook et 
al., 2014b; Cohen et al., 2013).  The future of tau research will rely on further exploring this 
interplay, and defining the patterns of tau PTMs that keep it in the physiological state versus put 
it in a pathological state. 
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Figures 
 
 
Figure 1. Tau acetylation mimetics K280Q and K280Q/K281Q impairs tubulin 
polymerization. (a-b) Light scattering assay in the presence of tau-K18 proteins detecting 
tubulin polymerization, as determined by absorbance readings at 350 nm (No Tau, (N=7); WT, 
(N=9); K280Q, (N=8); 2KQ, (N=4); K280R, (N=7); 2KR, (N=6)). Error bars indicate standard 
deviation (s.d.) of the mean. GraphPad t-test results are as follows:  WT v K280Q (***, p < 
0.0001); WT v K280R (ns, p = 0.36); K280Q v K280R (***, p < 0.0001); WT v 2KR (**, p = 
0.0072); WT v 2KQ (***, p < 0.0001); 2KQ v 2KR (***, p < 0.0001). 
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Figure 2: Tau acetylation mimetic K280Q displays accelerated aggregation compared to 
wild type tau and dense fibril formation without aid of heparin. (a-d) Coomassie blue 
staining of supernatant (S) and fibrillar pellet fractions of tau-K18 fibril reactions without 
heparin for (a) WT, (b) P301L, (c) K280Q protein from 0 – 2 day and (d) 4 day time points.  
One independent experiment.  (e) Negative stain electron microscopy of the 2 day K280Q 
fibrillization reaction.  One independent experiment. 
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Figure 3. K280Q tau enhances tau-K18 aggregation in vitro in presence of heparin. (a-d) 
Coomassie blue staining of supernatant (S) and fibrillar pellet fractions of tau-K18 fibril 
reactions with heparin for (a) WT, (b) P301L, (c) K280Q, and (d) K280R protein from 0 – 8 h 
time points.  Coomassie blue staining was repeated using a second set of fibril reactions. (e) 
Thioflavin T (ThT) fluorescence of tau-K18 fibril reactions at the indicated time points from 0 to 
8 h. Error bars indicate standard deviation (s.d.) of the mean. N=1 for each protein from three 
independent fibril reactions. 
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Figure 4. K280Q tau enhances full-length tau-T40 aggregation in vitro in presence of 
heparin. (a-c) Coomassie blue staining of supernatant (S) and fibrillar pellet fractions of tau-T40 
fibril reactions with heparin for (a) WT, (b) P301L, and (c) K280Q protein from 0 to 3 day fibril 
reactions. Coomassie blue staining for the 0, 1d, and 3d time points was also performed using a 
second set of fibril reactions. Results repeated in time points except that T40 PL 1 d for second 
set of fibril reactions is a bit slower to aggregate than the T40 PL 1 d that appears in above 
figure. (d) ThT fluorescence of tau-T40 fibril reactions at the indicated time points from 0 to 3 d. 
Error bars indicate standard deviation (s.d.) of the mean. N=1 for each protein from two sets of 
fibril reactions. 
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Figure 5. K280Q tau-K18 also enhances fibril formation in vitro in presence of heparin. (a-
b) Transmission electron microscopy of tau-K18 protein fibril reactions at (a) 2 h and (b) 4 h. 
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Figure 6. K280Q tau-K18 promotes pellet fraction rich in beta sheet structure. (a-d) CD 
spectra of tau-K18 at the indicated time points from 0 to 1 h (0 h, solid black line; 1 h, grey line) 
were recorded from 190 to 250 nm for (a) WT, (b) P301L, (c) K280Q, and (d) K280R. 0 h time 
points reflect soluble stock tau dialyzed against CD buffer and 1 h time points reflect pelleted 
fraction of sedimentation assays resuspended in CD buffer.  Error bars indicate standard 
deviation (s.d.) of the mean. N=3 for each time point.  
a b 
c d 
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Figure 7. Effects of methylene blue on tau-K18 solubility in vitro. (a-b) Coomassie blue 
staining of supernatant (S) and fibrillar pellet (P) fractions of tau-K18 fibril reactions plus or 
minus methylene blue for (a) WT and (b) K280Q.  One independent experiment. 
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Figure 8. Effects of insoluble tau-K18 fibrils on tau phosphorylation and solubility using 
QBI-293 cell seeding assay. (a-b) Western blot analysis of (a) Triton X-100 soluble protein 
fraction and (b) SDS soluble protein fraction with phospho-tau (AT8) antibody.  Cells were 
over-expressing tau-T40 mutant P301L and treated with tau-K18 fibrils (WT 24 h, K280Q 2 h, 
P301L 2 h, K280R 24 h) or a no fibril control.  N=2 per treatment, one independent experiment. 
  
a b 
44 
 
 
Figure 9. Effects of K280Q fibrils on full-length WT, K280Q and K280R full-length tau 
seeding in QBI-293 cells. (a-b) Western blot analysis of (a) soluble and (b) insoluble QBI-293 
cell lysate fractions with indicated antibodies of cells expressing tau T40 (WT, K280Q, or 
K280R) and treated with tau-K18 mutant K280Q fibrils.  Monomeric tau is between 50 kDa and 
75 kDa.  Asterisks in insoluble T46 blot indicate faint high molecular weight protein bands 
positive for T46.  N=3 per tau T40 plasmid transfection, one independent experiment. 
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Figure 10. Effects of K280Q and P301L fibrils on full-length WT, K280R-P301L, and 
P301L tau seeding in QBI 293 cells. (a-d) Western blot analysis of (a) soluble AT8, (b) 
insoluble AT8, (c) insoluble T46, and (d) insoluble tau-1 from QBI-293 lysate fractions of cells 
expressing tau T40 (WT, K280R-P301L, or P301L) and treated with tau-K18 fibrils (K280Q, 
N=2 or P301L, N=1) or a no fibril control, N=1. Molecular weights to left side of blots are in 
kDa.  One independent experiment. 
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Figure 11. Effects of K280Q and P301L fibrils upon injection into PS19 mice. 
Immunohistochemical analysis using AT8 tau antibody of PS19 mouse hippocampus injected 
with tau-K18 fibrils (K280Q 2 h or P301L 2 h) or a PBS control. Fibrils were injected into the 
ipsilateral side.  N=3 mice per treatment, one independent experiment. 
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Figure 12:  Early characterization of phospho-tau in mice containing P301S and K280Q 
mutant human tau. (a) Western blot analysis of P301S-K280Q primary neuron (DIV15) lysate 
with phospho-S396 tau antibody.  Lysate was from either untreated or fibril treated neurons as 
indicated.  (b) Western blot analysis of CD-1, P301S, and P301S-K280Q primary neurons with 
phospho-S396 tau antibody.  The lysates were not treated with fibrils.  CD-1 and P301S lysates 
were from an unknown DIV and P301S-K280Q lysates were from DIV15.  CD-1 and P301S 
were kindly provided by Jui-Heng Tseng from my lab.  One independent experiment. 
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